Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cinaciguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.61 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 6/20 | 0.44 |
| ▸ | RXRB | P28702 | 5/20 | 0.44 |
| ▸ | RXRG | P48443 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinaciguat SCHEMBL249267 | 0.99 | PTGER1 (0.62) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL13009539 | 0.97 | PTGER1 (0.61) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL2982959 | 0.95 | PTGER1 (0.57) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL13009831 | 0.94 | PTGER1 (0.56) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL29748782 | 0.94 | PTGER1 (0.53) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL13009672 | 0.93 | PTGER1 (0.57) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009661 | 0.92 | PTGER1 (0.55) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009719 | 0.91 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009681 | 0.91 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009666 | 0.91 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | claimed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | claimed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | disclosed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| US-7781470-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-24 | — | — | US | disclosed |
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER AKTIENGESELLSCHAFT (DE) | 2009-08-13 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7087644-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203906-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | PTGER1 27/4885PTGER4 21/4885PTGER3 48/4885 |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | PTGER1 697/4885PTGER4 953/4885PTGER3 923/4885 |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | DDC, AADAT, PTGIS | PTGER1 27/4885PTGER4 21/4885PTGER3 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.